Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 8/20 | 0.45 |
| ▸ | NOS3 | P29474 | 7/20 | 0.45 |
| ▸ | NOS1 | P29475 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | DCK | P27707 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2623102 | 0.84 | NOS2 (0.54) | NOS2NOS3NOS1NPC1RAB9A | |
| SCHEMBL9971004 | 0.84 | PTGS2 (0.36) | NOS2NOS3NOS1NPC1RAB9A | |
| SCHEMBL10264324 | 0.78 | ACHE (0.36) | NPC1RAB9ASMN1; SMN2LOXL2MAPT | |
| SCHEMBL15649816 | 0.78 | LOXL2 (0.32) | NPC1RAB9ASMN1; SMN2LOXL2MAPT | |
| SCHEMBL15650304 | 0.78 | RAB9A (0.36) | NPC1RAB9ASMN1; SMN2DCK | |
| SCHEMBL15650100 | 0.76 | RIPK2 (0.32) | — | |
| SCHEMBL10264197 | 0.76 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL21672278 | 0.76 | NOS2 (0.54) | NOS2NOS3NOS1NPC1RAB9A | |
| SCHEMBL2623106 | 0.76 | NOS2 (0.63) | NOS2NOS3NOS1 | |
| SCHEMBL12808293 | 0.74 | NOS2 (0.45) | NOS2NOS3NOS1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180015093-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-9738634-B2 | Heterocyclic amide compound and herbicide | SYNGENTA PARTICIPATIONS AG (CH) | 2017-08-22 | — | — | US | disclosed |
| US-20160221998-A1 | HETEROCYCLIC AMIDE COMPOUND AND HERBICIDE | SYNGENTA PARTICIPATIONS AG (CH) | 2016-08-04 | — | — | US | disclosed |
| EP-3045455-A1 | HETEROCYCLIC AMIDE COMPOUND AND HERBICIDE | Syngenta Participations AG (CH) | 2016-07-20 | — | — | EP | disclosed |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2012-12-27 | — | — | US | disclosed |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2012-09-27 | — | — | US | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8193182-B2 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | INTELLIKINE, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | NOS2 3566/4885NOS3 2328/4885NOS1 4084/4885 |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | NOS2 3084/4885NOS3 931/4885NOS1 2561/4885 |
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | NOS2 3921/4885NOS3 1246/4885NOS1 3909/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | NOS2 2455/4885NOS3 1630/4885NOS1 2409/4885 |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | NOS2 3566/4885NOS3 2328/4885NOS1 4084/4885 |
| US-20160221998-A1 | HETEROCYCLIC AMIDE COMPOUND AND HERBICIDE | GLRA1, RER1, H1-4 | NOS2 1438/4885NOS3 1316/4885NOS1 890/4885 |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | NOS2 3921/4885NOS3 1246/4885NOS1 3909/4885 |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | NOS2 3923/4885NOS3 1640/4885NOS1 3987/4885 |
| US-20180015093-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | NOS2 4645/4885NOS3 4398/4885NOS1 4656/4885 |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | NOS2 3326/4885NOS3 2789/4885NOS1 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.